Top 10 Companies in the Protein G, L, and A Resin Market (2026): Market Leaders Driving Global Biopharma Purification

In Business Insights
August 08, 2026

MARKET INSIGHTS

Global Protein G, L, and A Resin market size was valued at USD 850 million in 2025 and is projected to reach USD 1.61 billion by 2034, exhibiting a CAGR of 7.8% during the forecast period from 2026 to 2034.

Protein G, L, and A Resins are specialized affinity chromatography media critical for the purification of antibodies in biopharmaceutical manufacturing and research. These recombinant or native proteins are immobilized onto a solid support to selectively bind immunoglobulins. Protein A resin is the industry standard for purifying monoclonal antibodies, binding primarily to the Fc region of IgG. Protein G resin offers a broader binding profile for various IgG subclasses, while Protein L resin is uniquely capable of binding antibodies through their kappa light chains, making it essential for certain antibody fragments and recombinant formats.

Market growth is driven by the expanding pipeline of biologics and monoclonal antibody therapeutics, which require highly efficient and scalable purification processes. Rising R&D investments in oncology and immunology further propel demand. Strategic developments, such as high‑capacity, alkali‑stable resins that improve cleaning‑in‑place protocols, enhance process economics. For instance, in 2025, Repligen Corporation expanded its Protein A resin portfolio with a new offering designed for increased dynamic binding capacity, directly addressing the needs of high‑titer cell culture processes. Leading companies like Cytiva, Thermo Fisher Scientific, and Merck KGaA dominate the market with comprehensive product lines and global supply chains.

Protein G, L, And A Resin Market – View in Detailed Research Report

Top 10 Companies in the Protein G, L, and A Resin Market

  1. Cytiva (Danaher)

    Headquarters: Irving, Texas, USA
    Key Offering: Protein A, G, and L resins integrated with ÄKTA chromatography systems

    Cytiva’s portfolio spans the full spectrum of affinity media, enabling seamless scale‑up from pilot to commercial production. The company’s investment in ligand engineering has delivered resins with higher dynamic binding capacity and improved leachables profiles, directly translating into lower operating costs for biopharma manufacturers.

    Sustainability & Growth Initiatives:

    • Development of recyclable agarose matrices to reduce single‑use waste
    • Digital process analytics embedded in chromatography hardware for real‑time resin health monitoring
    • Expansion of the ÄKTA line to support continuous manufacturing workflows
  2. Merck KGaA

    Headquarters: Darmstadt, Germany
    Key Offering: High‑capacity, low‑leach Protein A resins for ultra‑pure monoclonal antibody production

    Merck’s focus on ligand stability and low‑leach chemistry aligns with the stringent quality requirements of biopharmaceuticals. The company’s global distribution network ensures rapid replenishment, a critical advantage for manufacturers operating in multiple regions.

    Sustainability & Growth Initiatives:

    • Implementation of green chemistry principles in resin synthesis
    • Partnerships with CDMOs to offer turnkey purification solutions
    • Continuous improvement of cleaning‑in‑place protocols to lower water and chemical consumption
  3. Thermo Fisher Scientific

    Headquarters: Waltham, Massachusetts, USA
    Key Offering: SureSelect and ProSep families of Protein A, G, and L resins

    Thermo Fisher’s proprietary resins are engineered for compatibility with automated chromatography platforms, enabling high‑throughput processing and reducing manual intervention. The company’s R&D pipeline includes next‑generation ligands with enhanced pH tolerance.

    Sustainability & Growth Initiatives:

    • Adoption of biodegradable polymer supports in resin manufacturing
    • Integration of AI‑driven predictive models for resin cycle optimization
    • Strategic acquisitions of niche affinity media developers
  4. Repligen Corporation

    Headquarters: Waltham, Massachusetts, USA
    Key Offering: Modular purification kits and high‑dynamic binding capacity Protein A resins

    Repligen’s modular approach accelerates process development for early‑stage therapeutic candidates. The company’s recent launch of a high‑capacity Protein A resin has shortened validation timelines for biopharma developers.

    Sustainability & Growth Initiatives:

    • Deployment of single‑use resin cartridges to reduce cleaning burden
    • Collaboration with CDMOs to standardize resin kits across global sites
    • Investment in digital process analytics for resin health monitoring
  5. Purolite Corporation

    Headquarters: Westerville, Ohio, USA
    Key Offering: Custom ion‑exchange‑based affinity media for atypical antibody formats

    Purolite’s expertise in ion‑exchange chemistry allows the company to tailor affinity media for challenging antibody fragments and recombinant proteins that fall outside conventional ligand frameworks.

    Sustainability & Growth Initiatives:

    • Use of renewable feedstocks in resin production
    • Partnerships with academic research institutes for ligand innovation
    • Development of low‑leach, high‑capacity resins for large‑scale bioprocesses
  6. GenScript

    Headquarters: Nanjing, China
    Key Offering: Proprietary Protein G and L resins optimized for high‑throughput screening

    GenScript’s transition from contract services to proprietary media has positioned it as a key supplier for academic and biotech laboratories seeking rapid, scalable purification solutions.

    Sustainability & Growth Initiatives:

    • Implementation of eco‑friendly resin synthesis routes
    • Collaboration with Chinese biotech incubators to accelerate product development
    • Focus on modular resin formats for flexible process scaling
  7. Abcam

    Headquarters: Cambridge, United Kingdom
    Key Offering: Ready‑to‑use resin beads for small‑scale laboratories

    Abcam’s bead‑based resins lower the entry barrier for academic users, expanding the addressable market for downstream purification solutions.

    Sustainability & Growth Initiatives:

    • Use of biodegradable support materials in bead production
    • Digital cataloguing of resin performance data for end‑users
    • Partnerships with university research centers to validate resin efficacy
  8. 3M

    Headquarters: Saint Paul, Minnesota, USA
    Key Offering: Advanced chromatography media and membrane technologies

    3M’s broad portfolio includes high‑performance resins that integrate with both batch and continuous chromatography systems, offering flexibility across production scales.

    Sustainability & Growth Initiatives:

    • Development of low‑leach, recyclable resin supports
    • Investments in water‑recycling technologies for resin cleaning
    • Digital process control solutions for resin life extension
  9. Sartorius

    Headquarters: Göttingen, Germany
    Key Offering: Chromatographic resins and automation platforms

    Sartorius combines resin chemistry with advanced automation, enabling high‑throughput purification in a single integrated system.

    Sustainability & Growth Initiatives:

    • Eco‑design of resin supports using renewable polymers
    • Digital twin technology for process optimization
    • Collaborations with CDMOs to offer turnkey purification solutions
  10. GE Healthcare Life Sciences

    Headquarters: Chicago, Illinois, USA
    Key Offering: Protein A resins compatible with large‑scale automation

    GE Healthcare’s resins are engineered for high‑capacity and low‑leach performance, supporting biopharma manufacturers’ demand for reliable downstream processing.

    Sustainability & Growth Initiatives:

    • Implementation of green chemistry in resin synthesis
    • Partnerships with continuous manufacturing partners
    • Focus on low‑water‑usage cleaning protocols

Download FREE Sample Report

Get Full Report

Market Outlook

The trajectory of the Protein G, L, and A Resin market reflects the broader evolution of biopharmaceutical manufacturing. As antibody therapeutics expand across oncology, immunology, and rare disease indications, the demand for high‑purity, high‑throughput purification platforms will intensify. The integration of continuous manufacturing and digital process control is expected to reshape downstream workflows, pushing suppliers to deliver resins that support automated, scalable operations. Geographic expansion, particularly in the Asia‑Pacific region, will further diversify the customer base, while sustainability pressures will drive innovation in recyclable and low‑leach resin chemistries.

Future Trends

  • Adoption of single‑use, high‑capacity resin formats to reduce cleaning‑in‑place cycles
  • Expansion of digital analytics and AI‑driven predictive maintenance for resin life extension
  • Growth of biosimilar production, creating demand for cost‑effective yet reliable affinity media
  • Increased collaboration between resin manufacturers and CDMOs to offer end‑to‑end purification solutions
  • Development of biodegradable support materials to align with regulatory and market sustainability expectations